New Liver Transplant Technology Eliminates Lifelong Immunosuppressant Drugs

A new immunomodulatory technique has enabled liver transplant recipients to stop taking lifelong immunosuppressant drugs, according to recent clinical research.

Researchers at the University of Pittsburgh reported that several liver transplant patients remained off anti-rejection medications for at least three years following an experimental therapy designed to train the immune system to accept the donated organ.

The approach, termed “BOOST” (Biological Orphan Organ Support Therapy), involves isolating regulatory T cells (Tregs) from the recipient’s blood prior to transplant. These cells are expanded in the laboratory using interleukin-2 (IL-2) and rapamycin, then reinfused alongside the donor liver to promote graft tolerance.

Early-phase clinical data indicate a fivefold improvement in graft function at one year post-transplant compared to standard care, reducing reliance on calcineurin inhibitors that carry nephrotoxic and metabolic risks.

By avoiding lifelong immunosuppressant drugs, patients may experience fewer side effects such as kidney damage, high blood pressure, and increased susceptibility to infection or cancer.

The technique aims to alleviate pressures on the global organ shortage by improving transplant longevity and reducing the need for retransplantation.

Over 10,000 patients await liver transplants annually in the United States alone, according to the research summary.

The findings were published in Nature Communications, where the study team described a single infusion as feasible and safe in adult living-liver donor transplantation recipients.

While the results are preliminary, researchers suggest the work could lead to a future where organ recipients are not burdened by lifelong medication regimens.